German drug maker Merck KGaA reported Tuesday net profit for the first quarter that declined 13 percent from last year, despite strong double-digit sales growth, reflecting weak margins amid financing costs incurred in advance of the planned acquisition of Sigma-Aldrich. However, earnings before interest, tax, depreciation and amortization or EBITDA increased 4.6 percent.